One-year cardiovascular event rates in outpatients with atherothrombosis.
By P. Steg, Deepak L. Bhatt, Peter W. F. Wilson, Ralph B. D’Agostino, E. Ohman, J. Röther, C. Liau, A. Hirsch, J. Mas, Y. Ikeda and 2 more. Journal of the American Medical Association (JAMA), 2007
1,249 citations recorded by the source corpus.
Subfields: Pulmonary and Respiratory Medicine, Surgery
View Paper: https://www.semanticscholar.org/paper/589eb8524fe5ff2adfe39ae92f87e9357be2a9af
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Surgery
Citations in the corpus
- A review on coronary artery disease, its risk factors, and therapeutics (2019, background): “In the year 2007, it has been reported that approximately one in 30 patients with CAD experiences death each year (Steg et al., 2007).”
- [2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS.] (2018, background): “The combination of symptomatic LEAD and CAD is associated with further heightened ischaemic risk beyond that associated with symptomatic disease in either vascular bed alone [243].”
- The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation: Endorsed by the Association for Research into Arterial Structure and Physiology (ARTERY) Society. (2015, background): “The risk for CV death, myocardial infarction, stroke and hospitalisation is approximately 12% with 1 vascular bed disease and approximately 26% with 3 vascular bed disease [232].”
- Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. (2018, neutral): “Major adverse limb events were also significantly lower in the low-dose rivaroxaban plus aspirin group compared with the aspirin alone group (30 [1”